TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03156296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
Study: NCT01286909

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LaFlavon
Description: two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
Study: NCT02464280

Intervention type: OTHER
Intervention: Tomosythesis scan of the lung or the wrist
Description: All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.

Intervention type: OTHER
Intervention: Tomosythesis scan of the lung or the wrist
Description: All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.

Intervention type: OTHER
Intervention: CT scan of the lung or the wrist
Description: All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.

Intervention type: OTHER
Intervention: CT scan of the lung or the wrist
Description: All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.

Intervention type: OTHER
Intervention: conventional X-ray of the lung or the wrist
Description: All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
Study: NCT03715647

Intervention type: OTHER
Intervention: Sepsis
Description: Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.

Intervention type: OTHER
Intervention: HELLP Syndrome
Description: Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
Study: NCT02464280

Intervention type: OTHER
Intervention: conventional X-ray of the lung or the wrist
Description: All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
Study: NCT04269798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Treatment
Description: conventional rehabilitation program for lower limb, balance and gait training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treatment
Description: conventional rehabilitation program for lower limb, balance and gait training
Study: NCT03715647

Intervention type: OTHER
Intervention: Respiratory Distress Syndrome Adult
Description: Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
Study: NCT02375334

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Medical chart review by the Cancer Center ORIS and EPIC based systems
Study: NCT03871218

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid group
Description: Applicaton of topical Hyaluronic acid
Study: NCT01765218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo identical in appearance to the active agent (topiramate)
Study: NCT04530136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruconest
Description: Patients will be randomized to Ruconest or Standard of Care

Intervention type: DRUG
Group type: OTHER
Intervention: Ruconest
Description: Patients will be randomized to Ruconest or Standard of Care
Study: NCT00648960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Single-dose 500 mg immediate-release oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Single-dose 500 mg immediate-release oral dose
Study: NCT03546452

Intervention type: DIAGNOSTIC_TEST
Intervention: in vitro NGS-panel
Description: cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel
Study: NCT00791817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: 200 mg capsule, single dose,fasted when dosed, duration is 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG-760564
Description: 200 mg capsule, single dose,high fat diet when dosed, duration is 4 days
Study: NCT01475149

Intervention type: OTHER
Intervention: Phlebotomy
Description: Subjects will have blood drawn at each of the 3 study visits.
Study: NCT02900716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRMWXHS-12
Description: DTRMWXHS-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRM-505
Description: DTRMWXHS-12 and everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRM-555
Description: DTRMWXHS-12 and everolimus and pomalidomide
Study: NCT01911091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
Study: NCT01691664

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Only radiation therapy
Description: Patients only radiation therapy after surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus DC-CIK cellular therapy
Description: Patients receive radiation therapy plus DC-CIK cellular therapy after surgery
Study: NCT03453736

Intervention type: OTHER
Intervention: No intervention
Description: This is a qualitative study involving staff interviews and observations. No intervention is being applied.

Intervention type: OTHER
Intervention: No intervention
Description: This is a qualitative study involving staff interviews and observations. No intervention is being applied.
Study: NCT01622322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: Subjects will receive General anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
Study: NCT05510492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDUCATION
Description: THE EXPERIMENT GROUP WAS GIVEN THEORETICAL AND APPLIED EDUCATION,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EDUCATION
Description: THE EXPERIMENT GROUP WAS GIVEN THEORETICAL AND APPLIED EDUCATION,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APPLIED EDUCATION
Description: the injection was applied on the model by the researcher with the demonstration method according to the Procedure Steps of Intramuscular Injection with the Z Technique from the Ventrogluteal Region. This process was first ensured by the nurses, and then
Study: NCT04695561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Myofascial Relaxation
Description: Total of 12 times for 6 weeks
Study: NCT04695561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Total of 12 times for 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only Exercise (Control)
Description: Every day for 6 weeks
Study: NCT04055883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229
Description: All participants are administered one tablet per day for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229
Description: All participants are administered one tablet per day for 96 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-1229
Description: All participants are administered one tablet per day for 96 weeks
Study: NCT03368417

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will be advised to measure their BP at least 3 times a week and record their results on a form. The participants will be educated on how to interpret their BP according to standard self-monitoring practice guidelines.~As part of the study, participants without a HBPM will be provided with the Omron HEM 7130. Adherence to hypertensive medicines will be monitored using the medication event monitoring system eCAP™. In addition, the participants will be asked to undertake ambulatory blood pressure monitoring (using the Welch Allyn ABPM 7100 monitor) at Baseline and Month 6 for a duration of 12 hours, during their waking hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will be advised to measure their BP at least 3 times a week and record their results on a form. The participants will be educated on how to interpret their BP according to standard self-monitoring practice guidelines.~As part of the study, participants without a HBPM will be provided with the Omron HEM 7130. Adherence to hypertensive medicines will be monitored using the medication event monitoring system eCAP™. In addition, the participants will be asked to undertake ambulatory blood pressure monitoring (using the Welch Allyn ABPM 7100 monitor) at Baseline and Month 6 for a duration of 12 hours, during their waking hours.
Study: NCT01821313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Exercise
Study: NCT03307135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single assessment with the MSPMI
Description: Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double assessment with the MSPMI with 7 days of interval
Description: Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double assessment with the MSPMI before and after treatment
Description: Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
Study: NCT05660876

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard fistulotomy
Description: in a standard manner fistula tract was identified and laid open without doing marsupialization

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard fistulotomy
Description: in a standard manner fistula tract was identified and laid open without doing marsupialization

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fistulotomy with marsupialization
Description: in this arm fistulotomy was done in a standard manner and marsupialization was done

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fistulotomy with marsupialization
Description: in this arm fistulotomy was done in a standard manner and marsupialization was done
Study: NCT04044937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 Fluoroethyltyrosine (FET)
Description: Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 Fluoroethyltyrosine (FET)
Description: Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner
Study: NCT01475149

Intervention type: OTHER
Intervention: Phlebotomy
Description: Subjects will have blood drawn at each of the 3 study visits.

Intervention type: OTHER
Intervention: Phlebotomy
Description: Subjects will have blood drawn at each of the 3 study visits.

Intervention type: OTHER
Intervention: Phlebotomy
Description: Subjects will have blood drawn at each of the 3 study visits.
Study: NCT04044937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: All patients receive single PET imaging lasting for 40 minutes. Acquired PET data will be reconstructed so that three time points are created: (1) Perfusion: 60-second acquisition that starts immediately when activity is noted in the field of view, (2) Equilibrium: 10-minute acquisition acquired between 10 and 20 minutes after injection, and (3) Washout: 10-minute acquisition acquired between 30 and 40 minutes after injection. A repeat PET image will be offered to adult patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: All patients receive single PET imaging lasting for 40 minutes. Acquired PET data will be reconstructed so that three time points are created: (1) Perfusion: 60-second acquisition that starts immediately when activity is noted in the field of view, (2) Equilibrium: 10-minute acquisition acquired between 10 and 20 minutes after injection, and (3) Washout: 10-minute acquisition acquired between 30 and 40 minutes after injection. A repeat PET image will be offered to adult patients.
Study: NCT01114555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Irinotecan and Temozolomide
Description: Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
Study: NCT03318172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator
Description: Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulator
Description: Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
Study: NCT03396562

Intervention type: OTHER
Intervention: Assessments of Development and Growth
Description: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 5 years, 6 years, 7 years, 8 years, 9 years of age.
Study: NCT00472238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: endurance training
Description: control group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: Treadmill exercise training to optimize physical endurance
Study: NCT02708056

Intervention type: DRUG
Group type: OTHER
Intervention: Sugammadex
Study: NCT03903146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Childhood Obesity Risk-Reduction Program in Hispanics
Description: Sessions Prenatal (40 min): Includes a colorful binder with information about breastfeeding. Set her goals and action plan for breastfeeding. Past experiences with breastfeeding. Benefits of adopting a healthy behavior, describe and discuss infant feeding and qualms about mixed feeding, barriers to EBF and self-efficacy.~Prenatal Calls (10 min.): Discuss strategies available to accomplish mother's breastfeeding goals. Answer questions. Follow-up call until delivery.~Hospital visit (30 min.): PC visit mother at the hospital stay to support the participant in her effort to breastfeeding.~Postpartum home-visit (40 min.) IBCLC performs a home visit to assess infant feeding pattern, breastfeeding techniques with hands-on assistance if needed. Provide supplemental breastfeeding devices as needed. Answer all questions.~Postpartum calls (10 min.): PC/IBCLC ask about problems/concerns and answer questions. Repeat phone calls as needed (at least 1 a month).
Study: NCT04292223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks
Study: NCT01401166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-Use Injection Device
Description: The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
Study: NCT01134705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol
Description: Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Aerosol
Description: HFA Vehicle Aerosol
Study: NCT01401166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-Use Injection Device
Description: The SID will be used, containing Herceptin 600 mg per 5 mL.
Study: NCT01789268

Intervention type: DEVICE
Intervention: Respiratory Inductive Plethysmography
Description: Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)

Intervention type: DEVICE
Intervention: Respiratory Inductive Plethysmography
Description: Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
Study: NCT03200223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized healthcare service
Description: Personalized healthcare service, such as exercise recommendation, lifestyle activity coaching, health data monitoring
Study: NCT02750293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Vitamin D preparation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05081687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: 5-FU 2400mg/m2; Oxaliplatin 85 mg/m2, Irinotecan 150mg/m2
Study: NCT03806816

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5 daily enteral doses of melatonin 10 mg/kg. (=2 ml/kg)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO group
Description: 5 daily enteral doses of placebo 2 ml/kg
Study: NCT02952417

Intervention type: OTHER
Intervention: Excess mortality
Description: Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
Study: NCT03062371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playgroup
Description: A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
Study: NCT04600037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Patients in group I received pregabalin at a dose of 75 mg twice daily during the first week that was increased to 150 mg twice daily thereafter and maintained at that level for 12 weeks.~Patients in two groups received exercise therapy (stretching exercises for the trapezius muscle). Patients were instructed to perform 10 repetitions three times a day., 3 months
Study: NCT01555814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: 4-week open label amisulpride treatment
Study: NCT04985162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Differential learning based physiotherapy to improve torso control, balance and gait

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Ordinary physiotherapy program